Bayer’s Adaptive Pathways Experience: 'Disappointing', But Valuable Lessons Learned
Executive Summary
Bayer outlined its initial experience with the European Medicines Agency’s adaptive pathways pilot at the recent DIA EuroMeeting in Glasgow, saying that the process had been “disappointing” but that it had learned some valuable lessons.